Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer-A Review

Despite current treatment strategies, the 5-year overall survival of muscle-invasive bladder cancer (MIBC) is approximately 50%. Historically, radical cystectomy (RC) with neoadjuvant chemotherapy has been the first-choice treatment for this patient group. Recently, several studies have reported enc...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2021-12, Vol.14 (1), p.38
Main Authors: van Hattum, Jons W, de Ruiter, Ben-Max, Oddens, Jorg R, Hulshof, Maarten C C M, de Reijke, Theo M, Bins, Adriaan D
Format: Article
Language:English
Subjects:
Antigens
Bladder cancer
Cancer therapies
Chemoradiotherapy
Chemotherapy
Clinical trials
Cytotoxicity
Immune checkpoint inhibitors
Immune system
Immunotherapy
Invasiveness
Lymphatic system
Medical prognosis
Metastases
Metastasis
Patients
Pelvis
Radiation therapy
Review
Survival
Tumor microenvironment
Tumors
Urothelial cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite current treatment strategies, the 5-year overall survival of muscle-invasive bladder cancer (MIBC) is approximately 50%. Historically, radical cystectomy (RC) with neoadjuvant chemotherapy has been the first-choice treatment for this patient group. Recently, several studies have reported encouraging results of using immune checkpoint inhibitors (ICI) prior to RC. However, in recent years, bladder-sparing alternatives such as CRT have gained popularity. The effect of radiotherapy on the tumor microenvironment is an important rationale for combining CRT with ICI therapy. Worldwide, twelve immunochemoradiotherapy (iCRT) trials are ongoing. Each study employs a different chemotherapy and radiotherapy regimen and varies the timing of ICI administration concurrent to radiotherapy, adjuvant, or both. Five studies have presented (preliminary) results showing promising safety and short-term survival data. The first peer-reviewed publications are expected in the near future. The preclinical evidence and preliminary patient data demonstrate the potential of iCRT bladder-sparing treatment for bladder cancer.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14010038